SanBio Company Limited Logo

SanBio Company Limited

Developing regenerative cell therapies for severe neurological disorders like brain injury and stroke.

4592 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
中央区明石町8番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SanBio Company Limited is a biotechnology firm dedicated to the research, development, production, and commercialization of regenerative cell medicines. The company focuses on creating novel treatments for severe neurological disorders, aiming to restore functions lost due to injury or disease. Its primary pipeline targets conditions affecting the central nervous system, such as chronic motor deficits resulting from traumatic brain injury and stroke. SanBio's lead product candidate, SB623 (marketed in Japan as AKUUGO®), is an allogeneic cell therapy developed to improve motor function in patients. The company leverages its proprietary technology for large-scale production to address significant unmet medical needs in neurology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 08:31
Regulatory News Service
確認書
Japanese 7.9 KB
2025-09-12 08:31
Interim Report
半期報告書-第13期(2025/02/01-2026/01/31)
Japanese 230.6 KB
2025-06-13 08:45
Regulatory News Service
臨時報告書
Japanese 19.2 KB
2025-04-24 08:31
Post-Annual General Meeting Information
臨時報告書
Japanese 23.7 KB
2025-04-23 08:31
Regulatory News Service
確認書
Japanese 8.0 KB
2025-04-23 08:31
Regulatory News Service
内部統制報告書-第12期(2024/02/01-2025/01/31)
Japanese 21.6 KB
2025-04-23 08:30
Annual Report
有価証券報告書-第12期(2024/02/01-2025/01/31)
Japanese 1.3 MB
2025-03-17 07:30
Earnings Release
臨時報告書
Japanese 21.2 KB
2025-02-14 07:30
Registration Form
有価証券届出書(参照方式)
Japanese 168.5 KB
2024-12-25 07:30
Regulatory News Service
臨時報告書
Japanese 19.3 KB
2024-12-02 07:30
Prospectus
有価証券届出書(参照方式)
Japanese 112.5 KB
2024-09-17 08:02
Regulatory News Service
臨時報告書
Japanese 19.0 KB
2024-09-17 08:01
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-09-17 08:01
Interim Report
半期報告書-第12期(2024/02/01-2024/07/31)
Japanese 181.0 KB
2024-06-13 08:02
Regulatory News Service
臨時報告書
Japanese 19.0 KB

Automate Your Workflow. Get a real-time feed of all SanBio Company Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SanBio Company Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.